
The interim analysis of the phase 3 COMMANDS trial compared the efficacy of luspatercept and epoetin alfa in treating anaemia in patients with lower-risk myelodysplastic syndromes (MDS). The study involved 356 patients who were randomly assigned to receive either luspatercept or epoetin alfa. The primary endpoint was achieving red blood cell transfusion independence for at least 12 weeks with a concurrent increase in hemoglobin levels. The analysis showed that luspatercept outperformed epoetin alfa, with 59% of patients in the luspatercept group achieving the primary endpoint compared to 31% in the epoetin alfa group. The most common adverse events were hypertension, anemia, dyspnea, and neutropenia. Further research is needed to confirm these findings and explore different patient subgroups.
Like
Save
Share